SlideShare una empresa de Scribd logo
1 de 23
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Published Chemotherapy Regimens Schedule 1 Cisplaitn 50 mg/m 2  days 1 and 8 Vinorelbine 25 mg/m 2  days 1, 8, 15, 22 Every 28 days for 4 cycles 2 Cisplaitn 100 mg/m 2  on day 1  Vinorelbine 30 mg/m 2  days 1, 8, 15, 22 Every 28 days for 4 cycles 3 Cisplaitn 75-80 mg/m 2  on day 1 Vinorelbine 25-30 mg/m 2  days 1, 8 Every 28 days for 4 cycles 4 Cisplaitn 100 mg/m 2  on day 1 Etoposide 100 mg/m 2  day 1-3 Every 28 days for 4 cycles 5 Cisplaitn 80 mg/m 2  day 1 Vinblastine 4 mg/m 2  days 1, 8, 15, 22 Every 28 days for 4 cycles Acceptable Cisplaitn-base Regimens 1 Cisplatin 80 mg/m 2  on day 1 Gemcitabine 1000 mg/m 2  on days 1, 8 Every 21 days 2 Cisplatin 80 mg/m 2 Docetaxel 75 mg/m 2 Every 21 days Chemotherapy Regimens for patients with comorbidities or patients not able to tolerate cisplatin 1 Paclitaxel 200 mg/m 2  on day 1 Carboplatin AUC 6 on day 1 Every 21 days
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object]
[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],Regimens Patients % 1 Gemcetabine + Cisplatin  29 30.53 2 Gemcetabine + Carboplatin  8 8.42 3 Gemcetabine + Platinum base + Radiotherapy 14 14.74 4 Gemcetabine + Platinum base + Avastin 4 4.21 5 Etoposite + Platinum base 15 15.79 6 Etoposite + Platinum base + Radiotherapy 2 2.10 7 Taxane base + Platinum base 14 14.74 8 Taxane base + Platinum base + Radiotherapy 6 6.31 9 Taxane base + Platinum base + Avastin 3 3.16
[object Object],Regimens  patients 1 Docetaxel 75-80 mg/ m 2   7 2 Irinotecan 200 mg/ m 2   3 3 Tarceva 150 mg/ m 2   5 4 Iressa 250 mg/ m 2   5
 
 
 
[object Object]
Regimes  GC GCar GPR GPA Total No. 29 8 14 4 No. % No. % No. % No. % Anaemia 4 13.79 1 12.50 4 28.57 - - Leucopenia 16 55.17 5 62.50 9 64.28 3 75 Lymphopenia 3 10.34 1 12.50 2 14.29 2 50 Thrombopenia 6 20.69 3 37.50 5 35.71 - - N & V 12 41.38 2 25.00 9 64.28 2 50 Increase Cr 4 13.79 1 12.50 3 21.43 - - Diarrhoea 2 6.90 - - 2 14.29 - - Hepatotoxicity 1 3.45 2 25.00 - - - - Fever 4 13.79 2 25.00 3 21.43 - - Nephrotoxicity 1 3.45 - - - - - - Fatigue  10 34.48 4 50.00 8 57.14 - -
 
Regimes  EP TP TPR Total No. 15 14 6 No. % No. % No. % Anaemia - - - - 1 16.67 Leucopenia - - 6 42.86 3 50 Thrombopenia - - - - 1 16.67 N & V 4 26.67 3 21.43 2 33.33 Diarrhoea - - - - 1 16.67 Fever 1 6.67 1 7.14 1 16.67 Nephrotoxicity 1 6.67 - - - - Neuropathy - - 3 21.43 - - Fatigue  - - 3 21.43 1 16.67 Myalgia - - 3 21.43 - -
 
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
 

Más contenido relacionado

La actualidad más candente

Melanoma frontline approach
Melanoma frontline approachMelanoma frontline approach
Melanoma frontline approachEreny Samwel
 
Olaparib in Metastatic Pancreatic Cancer
Olaparib in Metastatic Pancreatic Cancer Olaparib in Metastatic Pancreatic Cancer
Olaparib in Metastatic Pancreatic Cancer Chandan K Das
 
Multimodality Treatment Of Stage Iii Nsclc
Multimodality Treatment Of Stage Iii NsclcMultimodality Treatment Of Stage Iii Nsclc
Multimodality Treatment Of Stage Iii Nsclcfondas vakalis
 
Concurrent Chemoradiation in Postoperative Setting In LAHNC. A comparision of...
Concurrent Chemoradiation in Postoperative Setting In LAHNC. A comparision of...Concurrent Chemoradiation in Postoperative Setting In LAHNC. A comparision of...
Concurrent Chemoradiation in Postoperative Setting In LAHNC. A comparision of...Santam Chakraborty
 
RefractoryCRPC management
RefractoryCRPC managementRefractoryCRPC management
RefractoryCRPC managementChandan K Das
 
Allogeneic Stem Cell Transplant for Hodgkin's Lymphoma
Allogeneic Stem Cell Transplant for Hodgkin's LymphomaAllogeneic Stem Cell Transplant for Hodgkin's Lymphoma
Allogeneic Stem Cell Transplant for Hodgkin's Lymphomaspa718
 
Metronomic chemotherapy in mbc
Metronomic chemotherapy in mbcMetronomic chemotherapy in mbc
Metronomic chemotherapy in mbcmadurai
 
Metronomic Chemotherapy
Metronomic ChemotherapyMetronomic Chemotherapy
Metronomic ChemotherapySonali Karekar
 
Molecular Therapeutics with Chemotherapy in SCCHN by J. Vermorken
Molecular Therapeutics with Chemotherapy in SCCHN by J. VermorkenMolecular Therapeutics with Chemotherapy in SCCHN by J. Vermorken
Molecular Therapeutics with Chemotherapy in SCCHN by J. VermorkenEurasian Federation of Oncology
 
MCO 2011 - Slide 17 - J.B. Vermorken - Systemic therapy
MCO 2011 - Slide 17 - J.B. Vermorken - Systemic therapyMCO 2011 - Slide 17 - J.B. Vermorken - Systemic therapy
MCO 2011 - Slide 17 - J.B. Vermorken - Systemic therapyEuropean School of Oncology
 
ImmunoOncology in Lung Cancer
ImmunoOncology in Lung CancerImmunoOncology in Lung Cancer
ImmunoOncology in Lung Cancerspa718
 
Targeted Therapy for Melanoma - Dr. Michael Davies
Targeted Therapy for Melanoma - Dr. Michael DaviesTargeted Therapy for Melanoma - Dr. Michael Davies
Targeted Therapy for Melanoma - Dr. Michael DaviesMelanoma Research Foundation
 
Cetuximab in scchn how far we go?
Cetuximab in scchn  how far we go?Cetuximab in scchn  how far we go?
Cetuximab in scchn how far we go?Mohamed Abdulla
 
8 jason westin
8 jason westin8 jason westin
8 jason westinspa718
 
Peripheral Blood Stem Cell Transplant
Peripheral Blood Stem Cell TransplantPeripheral Blood Stem Cell Transplant
Peripheral Blood Stem Cell Transplantspa718
 

La actualidad más candente (20)

Melanoma frontline approach
Melanoma frontline approachMelanoma frontline approach
Melanoma frontline approach
 
Olaparib in Metastatic Pancreatic Cancer
Olaparib in Metastatic Pancreatic Cancer Olaparib in Metastatic Pancreatic Cancer
Olaparib in Metastatic Pancreatic Cancer
 
Multimodality Treatment Of Stage Iii Nsclc
Multimodality Treatment Of Stage Iii NsclcMultimodality Treatment Of Stage Iii Nsclc
Multimodality Treatment Of Stage Iii Nsclc
 
Concurrent Chemoradiation in Postoperative Setting In LAHNC. A comparision of...
Concurrent Chemoradiation in Postoperative Setting In LAHNC. A comparision of...Concurrent Chemoradiation in Postoperative Setting In LAHNC. A comparision of...
Concurrent Chemoradiation in Postoperative Setting In LAHNC. A comparision of...
 
RefractoryCRPC management
RefractoryCRPC managementRefractoryCRPC management
RefractoryCRPC management
 
Cco melanoma
Cco melanomaCco melanoma
Cco melanoma
 
Allogeneic Stem Cell Transplant for Hodgkin's Lymphoma
Allogeneic Stem Cell Transplant for Hodgkin's LymphomaAllogeneic Stem Cell Transplant for Hodgkin's Lymphoma
Allogeneic Stem Cell Transplant for Hodgkin's Lymphoma
 
Metronomic chemotherapy in mbc
Metronomic chemotherapy in mbcMetronomic chemotherapy in mbc
Metronomic chemotherapy in mbc
 
1- mutahir tunio
 1- mutahir tunio 1- mutahir tunio
1- mutahir tunio
 
Metronomic Chemotherapy
Metronomic ChemotherapyMetronomic Chemotherapy
Metronomic Chemotherapy
 
Cancer gastrico adyuvancia
Cancer gastrico adyuvanciaCancer gastrico adyuvancia
Cancer gastrico adyuvancia
 
Molecular Therapeutics with Chemotherapy in SCCHN by J. Vermorken
Molecular Therapeutics with Chemotherapy in SCCHN by J. VermorkenMolecular Therapeutics with Chemotherapy in SCCHN by J. Vermorken
Molecular Therapeutics with Chemotherapy in SCCHN by J. Vermorken
 
MCO 2011 - Slide 17 - J.B. Vermorken - Systemic therapy
MCO 2011 - Slide 17 - J.B. Vermorken - Systemic therapyMCO 2011 - Slide 17 - J.B. Vermorken - Systemic therapy
MCO 2011 - Slide 17 - J.B. Vermorken - Systemic therapy
 
ImmunoOncology in Lung Cancer
ImmunoOncology in Lung CancerImmunoOncology in Lung Cancer
ImmunoOncology in Lung Cancer
 
Targeted Therapy for Melanoma - Dr. Michael Davies
Targeted Therapy for Melanoma - Dr. Michael DaviesTargeted Therapy for Melanoma - Dr. Michael Davies
Targeted Therapy for Melanoma - Dr. Michael Davies
 
Cetuximab in scchn how far we go?
Cetuximab in scchn  how far we go?Cetuximab in scchn  how far we go?
Cetuximab in scchn how far we go?
 
Systemic Therapy for Metastatic Disease
Systemic Therapy for Metastatic DiseaseSystemic Therapy for Metastatic Disease
Systemic Therapy for Metastatic Disease
 
Developing a Test to Predict Side Effects of Chemotherapy in Patients with Co...
Developing a Test to Predict Side Effects of Chemotherapy in Patients with Co...Developing a Test to Predict Side Effects of Chemotherapy in Patients with Co...
Developing a Test to Predict Side Effects of Chemotherapy in Patients with Co...
 
8 jason westin
8 jason westin8 jason westin
8 jason westin
 
Peripheral Blood Stem Cell Transplant
Peripheral Blood Stem Cell TransplantPeripheral Blood Stem Cell Transplant
Peripheral Blood Stem Cell Transplant
 

Destacado

Dosage Calculation Using Formula Method
Dosage Calculation Using Formula MethodDosage Calculation Using Formula Method
Dosage Calculation Using Formula Methodwindleh
 
B A S I C S O F Pharmacology
B A S I C S  O F  PharmacologyB A S I C S  O F  Pharmacology
B A S I C S O F PharmacologyBob Bin
 
Colorectal surgery and stomas
Colorectal surgery and stomasColorectal surgery and stomas
Colorectal surgery and stomasmeducationdotnet
 
Mdr tb & xdr tb ppt.
Mdr tb & xdr tb ppt. Mdr tb & xdr tb ppt.
Mdr tb & xdr tb ppt. Silajit Dutta
 
18 basics of pediatric airway anatomy, physiology and management
18 basics of pediatric airway anatomy, physiology and management18 basics of pediatric airway anatomy, physiology and management
18 basics of pediatric airway anatomy, physiology and managementDang Thanh Tuan
 
Introduction to basic principles of pharmacology
Introduction to basic principles of pharmacologyIntroduction to basic principles of pharmacology
Introduction to basic principles of pharmacologyBalmukund Thakkar
 

Destacado (14)

Dosage Calculation Using Formula Method
Dosage Calculation Using Formula MethodDosage Calculation Using Formula Method
Dosage Calculation Using Formula Method
 
Dosage Regimen
Dosage RegimenDosage Regimen
Dosage Regimen
 
B A S I C S O F Pharmacology
B A S I C S  O F  PharmacologyB A S I C S  O F  Pharmacology
B A S I C S O F Pharmacology
 
Colorectal surgery and stomas
Colorectal surgery and stomasColorectal surgery and stomas
Colorectal surgery and stomas
 
Mdr tb & xdr tb ppt.
Mdr tb & xdr tb ppt. Mdr tb & xdr tb ppt.
Mdr tb & xdr tb ppt.
 
Drug Calculation
Drug CalculationDrug Calculation
Drug Calculation
 
Mdr tuberculosis
Mdr tuberculosisMdr tuberculosis
Mdr tuberculosis
 
Pediatric Medication
Pediatric MedicationPediatric Medication
Pediatric Medication
 
18 basics of pediatric airway anatomy, physiology and management
18 basics of pediatric airway anatomy, physiology and management18 basics of pediatric airway anatomy, physiology and management
18 basics of pediatric airway anatomy, physiology and management
 
INTRODUCTION TO PHARMACOLOGY
INTRODUCTION TO PHARMACOLOGYINTRODUCTION TO PHARMACOLOGY
INTRODUCTION TO PHARMACOLOGY
 
An Introduction to Pharmacology
An Introduction to PharmacologyAn Introduction to Pharmacology
An Introduction to Pharmacology
 
Colorectal Cancer
Colorectal CancerColorectal Cancer
Colorectal Cancer
 
Introduction to basic principles of pharmacology
Introduction to basic principles of pharmacologyIntroduction to basic principles of pharmacology
Introduction to basic principles of pharmacology
 
Pediatric drug dose calculation
Pediatric drug dose calculationPediatric drug dose calculation
Pediatric drug dose calculation
 

Similar a Aung thiha soe

brenutuximab-journal club.pptx
brenutuximab-journal club.pptxbrenutuximab-journal club.pptx
brenutuximab-journal club.pptxssuserf649e6
 
Phase ii study of temozolomide and thalidomide
Phase ii study of temozolomide and thalidomidePhase ii study of temozolomide and thalidomide
Phase ii study of temozolomide and thalidomideseayat1103
 
( )Anal scc
( )Anal scc( )Anal scc
( )Anal sccBDU
 
Clinical Development of ADC Drugs Targeting TROP-2.pdf
Clinical Development of ADC Drugs Targeting TROP-2.pdfClinical Development of ADC Drugs Targeting TROP-2.pdf
Clinical Development of ADC Drugs Targeting TROP-2.pdfDoriaFang
 
Journal club on Ca Anal Canal
Journal club on Ca Anal CanalJournal club on Ca Anal Canal
Journal club on Ca Anal CanalDr Manas Dubey
 
Targeted Therapy for Uveal Melanoma - Richard Carvajal, MD
Targeted Therapy for Uveal Melanoma - Richard Carvajal, MDTargeted Therapy for Uveal Melanoma - Richard Carvajal, MD
Targeted Therapy for Uveal Melanoma - Richard Carvajal, MDMelanoma Research Foundation
 
Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Epit...
Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Epit...Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Epit...
Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Epit...European School of Oncology
 
Success story of m tor inhibitors in m rcc
Success story of m tor inhibitors in m rccSuccess story of m tor inhibitors in m rcc
Success story of m tor inhibitors in m rccMohamed Abdulla
 
BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer
BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer  BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer
BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer European School of Oncology
 
STUPP TRIAL - treatment of high grade glioma
STUPP TRIAL - treatment of high grade gliomaSTUPP TRIAL - treatment of high grade glioma
STUPP TRIAL - treatment of high grade gliomaDr. Pallavi Jain
 
Temozolomide and thalidomide for treatment of neuroendocrine tumor
Temozolomide and thalidomide for treatment of neuroendocrine tumorTemozolomide and thalidomide for treatment of neuroendocrine tumor
Temozolomide and thalidomide for treatment of neuroendocrine tumorseayat1103
 
Chemotherapy in gliomas
Chemotherapy in gliomas Chemotherapy in gliomas
Chemotherapy in gliomas Dr Boaz Vincent
 
Targeted therapy for Hodgkin’s Lymphoma
Targeted therapy for Hodgkin’s LymphomaTargeted therapy for Hodgkin’s Lymphoma
Targeted therapy for Hodgkin’s Lymphomaspa718
 
Targeted therapy for Hodgkin’s Lymphoma
Targeted therapy for Hodgkin’s LymphomaTargeted therapy for Hodgkin’s Lymphoma
Targeted therapy for Hodgkin’s Lymphomaspa718
 
070125 chemotherapy for hn scc2
070125 chemotherapy for hn scc2070125 chemotherapy for hn scc2
070125 chemotherapy for hn scc2Asha Jangam
 
Side Effects Management for the Ovarian Cancer Community
Side Effects Management for the Ovarian Cancer CommunitySide Effects Management for the Ovarian Cancer Community
Side Effects Management for the Ovarian Cancer Communitybkling
 
Pancreatic Cancer Are We Moving Forward Yet
Pancreatic Cancer Are We Moving Forward YetPancreatic Cancer Are We Moving Forward Yet
Pancreatic Cancer Are We Moving Forward Yetfondas vakalis
 

Similar a Aung thiha soe (20)

brenutuximab-journal club.pptx
brenutuximab-journal club.pptxbrenutuximab-journal club.pptx
brenutuximab-journal club.pptx
 
Phase ii study of temozolomide and thalidomide
Phase ii study of temozolomide and thalidomidePhase ii study of temozolomide and thalidomide
Phase ii study of temozolomide and thalidomide
 
Portec 3
Portec 3Portec 3
Portec 3
 
( )Anal scc
( )Anal scc( )Anal scc
( )Anal scc
 
Erbitux
ErbituxErbitux
Erbitux
 
IO en NSCLC
IO en NSCLCIO en NSCLC
IO en NSCLC
 
Clinical Development of ADC Drugs Targeting TROP-2.pdf
Clinical Development of ADC Drugs Targeting TROP-2.pdfClinical Development of ADC Drugs Targeting TROP-2.pdf
Clinical Development of ADC Drugs Targeting TROP-2.pdf
 
Journal club on Ca Anal Canal
Journal club on Ca Anal CanalJournal club on Ca Anal Canal
Journal club on Ca Anal Canal
 
Targeted Therapy for Uveal Melanoma - Richard Carvajal, MD
Targeted Therapy for Uveal Melanoma - Richard Carvajal, MDTargeted Therapy for Uveal Melanoma - Richard Carvajal, MD
Targeted Therapy for Uveal Melanoma - Richard Carvajal, MD
 
Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Epit...
Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Epit...Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Epit...
Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Epit...
 
Success story of m tor inhibitors in m rcc
Success story of m tor inhibitors in m rccSuccess story of m tor inhibitors in m rcc
Success story of m tor inhibitors in m rcc
 
BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer
BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer  BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer
BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer
 
STUPP TRIAL - treatment of high grade glioma
STUPP TRIAL - treatment of high grade gliomaSTUPP TRIAL - treatment of high grade glioma
STUPP TRIAL - treatment of high grade glioma
 
Temozolomide and thalidomide for treatment of neuroendocrine tumor
Temozolomide and thalidomide for treatment of neuroendocrine tumorTemozolomide and thalidomide for treatment of neuroendocrine tumor
Temozolomide and thalidomide for treatment of neuroendocrine tumor
 
Chemotherapy in gliomas
Chemotherapy in gliomas Chemotherapy in gliomas
Chemotherapy in gliomas
 
Targeted therapy for Hodgkin’s Lymphoma
Targeted therapy for Hodgkin’s LymphomaTargeted therapy for Hodgkin’s Lymphoma
Targeted therapy for Hodgkin’s Lymphoma
 
Targeted therapy for Hodgkin’s Lymphoma
Targeted therapy for Hodgkin’s LymphomaTargeted therapy for Hodgkin’s Lymphoma
Targeted therapy for Hodgkin’s Lymphoma
 
070125 chemotherapy for hn scc2
070125 chemotherapy for hn scc2070125 chemotherapy for hn scc2
070125 chemotherapy for hn scc2
 
Side Effects Management for the Ovarian Cancer Community
Side Effects Management for the Ovarian Cancer CommunitySide Effects Management for the Ovarian Cancer Community
Side Effects Management for the Ovarian Cancer Community
 
Pancreatic Cancer Are We Moving Forward Yet
Pancreatic Cancer Are We Moving Forward YetPancreatic Cancer Are We Moving Forward Yet
Pancreatic Cancer Are We Moving Forward Yet
 

Más de zawhtet1984

Tanl power point
Tanl power pointTanl power point
Tanl power pointzawhtet1984
 
Pyae phyo aung's thesis (breast cancer)
Pyae phyo aung's thesis (breast cancer)Pyae phyo aung's thesis (breast cancer)
Pyae phyo aung's thesis (breast cancer)zawhtet1984
 
Powerpoint presentation by dr sathiha
Powerpoint presentation by dr sathihaPowerpoint presentation by dr sathiha
Powerpoint presentation by dr sathihazawhtet1984
 
Aung myo zaw(nutrition in preterm and congenital hypotrophy)
Aung myo zaw(nutrition in  preterm and congenital hypotrophy)Aung myo zaw(nutrition in  preterm and congenital hypotrophy)
Aung myo zaw(nutrition in preterm and congenital hypotrophy)zawhtet1984
 

Más de zawhtet1984 (11)

Yehlaingbwar
YehlaingbwarYehlaingbwar
Yehlaingbwar
 
Tanl power point
Tanl power pointTanl power point
Tanl power point
 
Kyaw thura zaw
Kyaw thura zawKyaw thura zaw
Kyaw thura zaw
 
Pyae phyo aung's thesis (breast cancer)
Pyae phyo aung's thesis (breast cancer)Pyae phyo aung's thesis (breast cancer)
Pyae phyo aung's thesis (breast cancer)
 
Zaw htet
Zaw htetZaw htet
Zaw htet
 
Sithu ko
Sithu koSithu ko
Sithu ko
 
Powerpoint presentation by dr sathiha
Powerpoint presentation by dr sathihaPowerpoint presentation by dr sathiha
Powerpoint presentation by dr sathiha
 
Khant zaw aung
Khant zaw aungKhant zaw aung
Khant zaw aung
 
Chan myae htut
Chan myae htutChan myae htut
Chan myae htut
 
Aung myo zaw(nutrition in preterm and congenital hypotrophy)
Aung myo zaw(nutrition in  preterm and congenital hypotrophy)Aung myo zaw(nutrition in  preterm and congenital hypotrophy)
Aung myo zaw(nutrition in preterm and congenital hypotrophy)
 
Aung citt nyein
Aung citt nyeinAung citt nyein
Aung citt nyein
 

Último

Hybridoma Technology ( Production , Purification , and Application )
Hybridoma Technology  ( Production , Purification , and Application  ) Hybridoma Technology  ( Production , Purification , and Application  )
Hybridoma Technology ( Production , Purification , and Application ) Sakshi Ghasle
 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityGeoBlogs
 
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions  for the students and aspirants of Chemistry12th.pptxOrganic Name Reactions  for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions for the students and aspirants of Chemistry12th.pptxVS Mahajan Coaching Centre
 
How to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptxHow to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptxmanuelaromero2013
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxiammrhaywood
 
Student login on Anyboli platform.helpin
Student login on Anyboli platform.helpinStudent login on Anyboli platform.helpin
Student login on Anyboli platform.helpinRaunakKeshri1
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...EduSkills OECD
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104misteraugie
 
Z Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot GraphZ Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot GraphThiyagu K
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introductionMaksud Ahmed
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactPECB
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxpboyjonauth
 
Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Celine George
 
Separation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and ActinidesSeparation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and ActinidesFatimaKhan178732
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdfQucHHunhnh
 
Arihant handbook biology for class 11 .pdf
Arihant handbook biology for class 11 .pdfArihant handbook biology for class 11 .pdf
Arihant handbook biology for class 11 .pdfchloefrazer622
 
URLs and Routing in the Odoo 17 Website App
URLs and Routing in the Odoo 17 Website AppURLs and Routing in the Odoo 17 Website App
URLs and Routing in the Odoo 17 Website AppCeline George
 

Último (20)

Hybridoma Technology ( Production , Purification , and Application )
Hybridoma Technology  ( Production , Purification , and Application  ) Hybridoma Technology  ( Production , Purification , and Application  )
Hybridoma Technology ( Production , Purification , and Application )
 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activity
 
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions  for the students and aspirants of Chemistry12th.pptxOrganic Name Reactions  for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
 
How to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptxHow to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptx
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
 
Student login on Anyboli platform.helpin
Student login on Anyboli platform.helpinStudent login on Anyboli platform.helpin
Student login on Anyboli platform.helpin
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104
 
Z Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot GraphZ Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot Graph
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introduction
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptx
 
Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17
 
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
 
Separation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and ActinidesSeparation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and Actinides
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
 
Arihant handbook biology for class 11 .pdf
Arihant handbook biology for class 11 .pdfArihant handbook biology for class 11 .pdf
Arihant handbook biology for class 11 .pdf
 
Staff of Color (SOC) Retention Efforts DDSD
Staff of Color (SOC) Retention Efforts DDSDStaff of Color (SOC) Retention Efforts DDSD
Staff of Color (SOC) Retention Efforts DDSD
 
URLs and Routing in the Odoo 17 Website App
URLs and Routing in the Odoo 17 Website AppURLs and Routing in the Odoo 17 Website App
URLs and Routing in the Odoo 17 Website App
 
Mattingly "AI & Prompt Design: The Basics of Prompt Design"
Mattingly "AI & Prompt Design: The Basics of Prompt Design"Mattingly "AI & Prompt Design: The Basics of Prompt Design"
Mattingly "AI & Prompt Design: The Basics of Prompt Design"
 

Aung thiha soe

  • 1.
  • 2.
  • 3.
  • 4. Published Chemotherapy Regimens Schedule 1 Cisplaitn 50 mg/m 2 days 1 and 8 Vinorelbine 25 mg/m 2 days 1, 8, 15, 22 Every 28 days for 4 cycles 2 Cisplaitn 100 mg/m 2 on day 1 Vinorelbine 30 mg/m 2 days 1, 8, 15, 22 Every 28 days for 4 cycles 3 Cisplaitn 75-80 mg/m 2 on day 1 Vinorelbine 25-30 mg/m 2 days 1, 8 Every 28 days for 4 cycles 4 Cisplaitn 100 mg/m 2 on day 1 Etoposide 100 mg/m 2 day 1-3 Every 28 days for 4 cycles 5 Cisplaitn 80 mg/m 2 day 1 Vinblastine 4 mg/m 2 days 1, 8, 15, 22 Every 28 days for 4 cycles Acceptable Cisplaitn-base Regimens 1 Cisplatin 80 mg/m 2 on day 1 Gemcitabine 1000 mg/m 2 on days 1, 8 Every 21 days 2 Cisplatin 80 mg/m 2 Docetaxel 75 mg/m 2 Every 21 days Chemotherapy Regimens for patients with comorbidities or patients not able to tolerate cisplatin 1 Paclitaxel 200 mg/m 2 on day 1 Carboplatin AUC 6 on day 1 Every 21 days
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.  
  • 12.  
  • 13.  
  • 14.
  • 15. Regimes GC GCar GPR GPA Total No. 29 8 14 4 No. % No. % No. % No. % Anaemia 4 13.79 1 12.50 4 28.57 - - Leucopenia 16 55.17 5 62.50 9 64.28 3 75 Lymphopenia 3 10.34 1 12.50 2 14.29 2 50 Thrombopenia 6 20.69 3 37.50 5 35.71 - - N & V 12 41.38 2 25.00 9 64.28 2 50 Increase Cr 4 13.79 1 12.50 3 21.43 - - Diarrhoea 2 6.90 - - 2 14.29 - - Hepatotoxicity 1 3.45 2 25.00 - - - - Fever 4 13.79 2 25.00 3 21.43 - - Nephrotoxicity 1 3.45 - - - - - - Fatigue 10 34.48 4 50.00 8 57.14 - -
  • 16.  
  • 17. Regimes EP TP TPR Total No. 15 14 6 No. % No. % No. % Anaemia - - - - 1 16.67 Leucopenia - - 6 42.86 3 50 Thrombopenia - - - - 1 16.67 N & V 4 26.67 3 21.43 2 33.33 Diarrhoea - - - - 1 16.67 Fever 1 6.67 1 7.14 1 16.67 Nephrotoxicity 1 6.67 - - - - Neuropathy - - 3 21.43 - - Fatigue - - 3 21.43 1 16.67 Myalgia - - 3 21.43 - -
  • 18.  
  • 19.
  • 20.
  • 21.
  • 22.
  • 23.